Sobhani Navid, Generali Daniele, Zanconati Fabrizio, Bortul Marina, Scaggiante Bruna
Department of Medical, Surgical and Health Sciences, University of Trieste, Cattinara Academic Hospital, Trieste 34149, Italy.
Department of Life Sciences, University of Trieste, Trieste 34127, Italy.
World J Clin Oncol. 2018 Apr 10;9(2):26-32. doi: 10.5306/wjco.v9.i2.26.
Breast cancer (BC) is the most common cancer and the second cause of death in women worldwide. Therapeutic options are increasing, but the response to treatments is not always efficient and the risk of recurrence covers decades. In this perspective, the need to have a proper follow-up for the therapeutic responses and for anticipating recurrence it is urgent in the clinical setting. Liquid biopsy provides the basic principle for a non-invasive method for the routinely monitoring of BC. However, due to the heterogeneity of tumors during onset and progression, the search for tumor DNA mutations of targeted genes in plasma/serum is a limiting factor. A possible approach overtaking this problem comes from the measurement of cell-free DNA integrity, which is an independent factor from the mutational status and theoretically is representative of all tumors. This review summarizes the state-of-the-art of cell-free DNA integrity researches in BC, the controversies and the future perspective.
乳腺癌（BC）是全球女性中最常见的癌症，也是第二大致死原因。治疗选择在不断增加，但治疗反应并不总是有效，复发风险长达数十年。从这个角度来看，在临床环境中，对治疗反应进行适当随访并预测复发的需求迫在眉睫。液体活检为乳腺癌的常规无创监测提供了基本原理。然而，由于肿瘤在发生和进展过程中的异质性，在血浆/血清中寻找靶向基因的肿瘤DNA突变是一个限制因素。解决这个问题的一种可能方法来自于对游离DNA完整性的测量，这是一个与突变状态无关的独立因素，理论上代表所有肿瘤。本文综述了乳腺癌中游离DNA完整性研究的现状、争议及未来展望。
